Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
What we are looking for: Were seeking an experienced Hub Engagement Manager to join NRC Switzerland on a 50% basis. This is an exciting opportunity for an energetic, highly organised and relationship-focused professional who thrives at
Company Description MF Group is a subsidiary of Riverty and part of the Bertelsmann Group. Around 120 employees work across two locations in Switzerland to make invoice-based purchasing with flexible installment payments even simpler and safer
Company Description MF Group is a subsidiary of Riverty and part of the Bertelsmann Group. Around 120 employees work across two locations in Switzerland to make invoice-based purchasing with flexible installment payments even simpler and safer
Company Description Die MF Group ist eine Tochtergesellschaft von Riverty und Teil des weltweit tätigen Bertelsmann-Konzerns und beschäftigt rund 100 Mitarbeitende an zwei Standorten in der Schweiz. Sie ist der führende Schweizer Anbieter für Kauf auf
Company Description MF Group is a subsidiary of Riverty and part of the Bertelsmann Group. Around 120 employees work across two locations in Switzerland to make invoice-based purchasing with flexible installment payments even simpler and safer
Do you want to dive in the fast-growing industry of drones and get a rewarding experience in a dynamic scale-up environment? At Flyability, we believe that robots should be sent into hazardous places and dangerous environments
La Cote International School (LCIS) is a school that aims to make a difference every day. We are passionate about education and seeing young people grow and develop, and we want the same for our colleagues.
Overview Reporting to the Sr. Director of Global Human Factors & Usability Engineering, the Staff Engineer (based in Cressier - Switzerland) will lead Human Factors Engineering (HFE) activities and design validation for IVD medical devices, ensuring
Company Description MF Group is a subsidiary of Riverty and part of the Bertelsmann Group. Around 120 employees work across two locations in Switzerland to make invoice-based purchasing with flexible installment payments even simpler and safer
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Standort: Zürich, Wien oder Hamburg Über die Position Du möchtest das Wachstum eines führenden FMCG-Unternehmens aktiv mitgestalten und übernimmst gerne Verantwortung für den kommerziellen Erfolg deiner Kunden? Du baust langfristige Partnerschaften auf, führst strategische Verhandlungen und
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)